Introduction {#sec1_1}
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Pyogenic granuloma (PG) was described for the first time in 1879 by Ponect and Dor and was called 'botryomycosis hominis' \[[@B1]\]. Crocker suggested the nomenclature of pyogenic granuloma in 1903 \[[@B2]\]. However, some researchers believe that Hatrzell introduced the term of pyogenic granuloma in 1904 \[[@B3]\]. PG is a common tumor-like growth affecting oral and extraoral sites \[[@B4], [@B5]\]. Traditionally, these lesions have been considered to be nonneoplastic in nature and thought to represent a tissue growth response to local irritation or trauma \[[@B4], [@B5]\]. The name 'pyogenic granuloma' is a misnomer since the condition is not caused by infection, does not associate with pus clinically and does not histologically represent a granulomatous inflammation \[[@B4], [@B6]\]. Clinically, PG is smooth or lobulated, sessile or pedunculated, as well as dull pink to red in color, with occasional surface ulcerations \[[@B4], [@B6]\]. Commonly, the lesions are painless but bleed easily due to extreme vascularity \[[@B4]\]. They may develop at any age, but more commonly occur in younger females and children \[[@B4], [@B6]\]. Intraorally, the typical site for involvement is the gingiva, with a higher prevalence in the maxilla than in the mandible \[[@B4], [@B6]\]. Other locations include the lips, buccal mucosa, and tongue \[[@B4]\]. Extraorally, these lesions are more commonly seen on the skin and rarely in the gastrointestinal tract, except the oral cavity \[[@B7]\]. The exact etiopathogenesis remains unexplained, and several factors appear to be related to their formation \[[@B8]\]. Many previous reports have suggested trauma, chronic irritation, hormones, drugs, calculus, foreign material in the gingival crevice, gingival irritation and inflammation caused by poor oral hygiene, and injury to primary teeth to be associated with the initiation of PG \[[@B1], [@B4], [@B9], [@B10], [@B11], [@B12]\].

This paper describes our experience in treating a case of recurrent PG with corticosteroids after surgical excision was challenged due to the poor outcome.

Case Report {#sec1_2}
===========

A 51-year-old Caucasian female was referred to the Oral Medicine Clinic for the evaluation of recurring PG on the buccal and palatal gingiva between the maxillary right bicuspid teeth. The lesion had been excised 4 times, and the diagnosis was confirmed histologically. The patient was submitted to the Oral Pathology Department at the University of Maryland Baltimore. Microscopic examination of different recurrent tissue specimens of the same lesion, using hematoxylin and eosin stain (H&E), revealed hyperplastic surface epithelium with highly vascular proliferation that resembles granulation tissue with numerous small and large endothelium-lined channels (fig. [1a](#F1){ref-type="fig"}). Mixed inflammatory cell infiltrates containing neutrophils, lymphocytes, and macrophages were observed (fig. [1b](#F1){ref-type="fig"}). All previous biopsy specimens were defined as PG. After 4 recurrences, the patient was referred to the Oral Medicine Clinic for further follow-up (the patient\'s past medical history was unremarkable and noncontributory). On the initial visit, she presented with a recurrent reddish, asymptomatic gingival growth measuring 0.9 × 0.6 cm on the buccal and 0.8 × 0.7 cm on the palatal aspect between the maxillary bicuspids (fig. [2a](#F2){ref-type="fig"}). Intralesional injections of 0.1 ml of 10 mg/ml triamcinolone acetonide injectable suspension (Kenalog-10) were performed at each of 5 different sites, with the total volume not exceeding 0.5 ml, and the patient was advised to use 0.05% clobetasol propionate ointment to be applied locally for 2 weeks. On the subsequent visit, after 3 weeks, the lesion had disappeared completely, and there was no recurrence. At the follow-up visit, the lesion had not recurred for a total of 6 weeks. Kenalog injections were no longer necessary at this time (fig. [2b](#F2){ref-type="fig"}). Also, the patient was instructed to discontinue the use of clobetasol ointment.

Discussion {#sec1_3}
==========

The study by Bhaskar et al. \[[@B2]\] of 242 patients with different oral lesions showed that PG was reported in 1.85% of all oral pathoses. Gingival lesions of 153 cases in the Southern Indian population were retrospectively analyzed. The authors found that 51% of gingival lesions were nonneoplastic, and PG was the most common diagnosis, accounting for 42.3% \[[@B13]\]. PGs can be treated in different ways, but conservative surgical excision and the removal of irritation factors are the usual treatment \[[@B4], [@B6]\]. For gingival lesions, excision should be extended deeply to the periosteum and adjacent teeth to remove the irritation source and prevent lesion recurrence \[[@B4]\]. Occasionally, PG recurs after surgical excision, and reexcision should be done. The recurrence rate after surgical treatment was noted to be 15.8% in a retrospective study of 242 cases, and it is more common after the excision of gingival lesions compared to the extragingival sites \[[@B2]\]. This unusual phenomenon of multiple PGs is known as satellitosis and usually develops as a complication of tumor removal or trauma \[[@B14], [@B15]\].

Other treatment options for PG have been introduced to replace surgical excision. In 1998, White et al. \[[@B16]\] showed that laser excision of PG is well tolerated by patients, with minimal side effects. Cryosurgery or the use of an electric scalpel has been reported to help in the complete resolution of PG \[[@B17]\]. Further, local injections of a sclerosing agent (monoethanolamine oleate) aided in the complete disappearance, with no recurrence in 9 patients \[[@B18]\]. Local injection of ethanol also appears to be an alternative therapy for PG \[[@B19]\]. Two extraoral PGs were reported to be reduced in size after multiple local intralesional steroid injections \[[@B20]\]. In 2004, Tursen et al. \[[@B21]\] reported a case with recurrent giant PG on the face, which had regressed in response to oral administration of systemic steroid treatment (prednisolone). In 2006, Parisi et al. \[[@B22]\] first described the use of a series of intralesional corticosteroid injections to treat multiple nodules of intraoral PGs, elucidating the new conservative treatment option. The exact mechanism of action of corticosteroid therapy is unknown. Corticosteroids might enhance the response of the lesion in the vascular bed to vasoconstricting agents \[[@B23]\]. In vitro and in vivo studies of hemangioma-derived stem cells showed that dexamethasone treatment inhibits the vasculogenic potential of hemangioma-derived stem cells. Also, dexamethasone arrests the vascular proliferation by downregulation of proangiogenic factors such as VEGF-A, MMP1, and IL-6 \[[@B24]\].

Based on this report, it can be inferred that multiple etiological factors might have played a role in the development of these large or recurrent lesions. However, treatment choice should consider the esthetic and functional improvement of the soft tissues with minimum invasion. Thus, we treated our case with a combination of antibiotics and steroids in order to relieve the microbial load of the lesions and gain maximum anti-inflammatory effects of the steroids to regress the lesion. Three weeks after the first visit, the lesion was completely healed. At the follow-up appointment, there was no recurrence, the patient was advised to discontinue both topical and local injections of steroids, and was placed on recall.

The drawbacks of our approach include the increased duration of disease management and, if this approach is used at the first clinical presentation, eliminate a histologically confirmed diagnosis prior to treatment. We recommend that in the treatment of PGs, the initial diagnosis should be confirmed histologically as they can be underdiagnosed for other more aggressive and even malignant lesions. However, when such lesions recur, a steroid management approach may be appropriate and safe. We conclude that steroid management may be considered as an alternative treatment approach for highly recurrent PGs in patients with proper medical and clinical evaluation.
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![Biopsy of the palatal gingiva between the maxillary right bicuspid teeth. **a** Photomicrograph showing hyperplastic surface epithelium with vascular proliferation and mixed inflammatory cells. H&E. ×10. **b** Photomicrograph showing small and large endothelium-lined channels and mixed inflammatory cell infiltrate. H&E. ×40.](cro-0008-0493-g01){#F1}

![Palatal gingiva. **a** Photograph showing 0.8 × 0.7 cm gingival growth on the palatal aspects between the maxillary bicuspids (before intralesional steroid injection). **b** Photograph showing disappearance of the lesions 3 weeks after steroid intralesional injection.](cro-0008-0493-g02){#F2}
